National Comprehensive Cancer Network



About NCCN

NCCN Flash Update: NCCN Guidelines and NCCN Compendium Updated

NCCN has published updates to the NCCN Guidelines for Non-Small Cell Lung Cancer. These NCCN Guidelines are currently available as Version 1.2011.

  • The evaluation process for systemic therapy for patients with recurrent or metastatic disease has changed to first determine histologic subtype and then recommend EGFR testing based on histologic subtype. EGFR testing is a category 1 recommendation for the following histologies: adenocarcinoma, large cell, and NSCLC NOS. EGFR testing is not recommended for squamous cell carcinoma.
  • The category designation for pemetrexed as an option for switch maintenance for patients with metastatic or recurrent adenocarcinoma, large cell, or NSCLC NOS was changed from a category 2B to a category 2A.
  • New pages were added to discuss the controversial issue of surgery in the management of patients with Stage IIIA (N2) disease.
  • Links were added to the new NCCN Guidelines for Patients™ with Non-Small Cell Lung Cancer.


NCCN has published updates to the NCCN Guidelines and the NCCN Drugs & Biologics Compendium (NCCN Compendium™) for Myelodysplastic Syndromes. These NCCN Guidelines are currently available as Version 2.2011.

  • “Consider evaluation of copper deficiency,” was added to the initial evaluation as helpful in some clinical situations.
  • The Panel added the WHO-Based Prognostic Scoring System (WPSS) for MDS Category 2B to the classification systems for de novo MDS, with the following footnote “IPSS should be used for initial prognostic and planning purposes. The WHO classification-based prognostic scoring system (WPSS) permits dynamic estimation of prognosis at multiple time points during the course of MDS.”


NCCN has published updates to the following chapter of the NCCN Compendium™ to reflect updates to the 2011 version of the corresponding NCCN Guidelines:

  • Cervical Cancer
  • Uterine Neoplasms


NCCN has published updates to the NCCN Guidelines for Colorectal Cancer Screening.  These NCCN Guidelines are currently available as Version 2.2011.

  • The Discussion section of the NCCN Guidelines for Colorectal Cancer Screening has been updated to correspond with the treatment algorithms.


For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.

Quick Links


About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2013 National Comprehensive Cancer Network, All Rights Reserved